LARS Antikörper (C-Term)
Kurzübersicht für LARS Antikörper (C-Term) (ABIN359572)
Target
Alle LARS Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- C-Term
-
Spezifität
- This antibody reacts to LARS.
-
Aufreinigung
- Prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS
-
Immunogen
- This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human LARS.
-
Isotyp
- Ig Fraction
-
-
-
-
Applikationshinweise
-
ELISA: 1/1,000. Western blotting: 1/50 - 1/100. Immunohistochemsitry: 1/10 - 1/50.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freezing and thawing.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
-
-
- LARS (Leucyl-tRNA Synthetase (LARS))
-
Andere Bezeichnung
- LARS
-
Hintergrund
- LARS, a cytosolic leucine-tRNA synthetase, a member of the class I aminoacyl-tRNA synthetase family. This enzyme catalyzes the ATP-dependent ligation of L-leucine to tRNA(Leu). It is found in the cytoplasm as part of a multisynthetase complex and interacts with the arginine tRNA synthetase through its C-terminal domain.Synonyms: EC=6.1.1.4, KIAA1352, LARS, LeuRS, Leucine-tRNA ligase, Leucyl-tRNA synthetase, cytoplasmic
-
Gen-ID
- 51520, 9606
-
UniProt
- Q9P2J5
-
Pathways
- EGFR Signaling Pathway
Target
-